Stephen Fawell Buys 62,000 Shares of CCCC
Stephen Fawell and other insiders purchase shares of CCCC, as analysts maintain bullish outlook.
Key Points
- Stephen Fawell bought 62,000 shares of CCCC on June 24, 2026, as part of recent insider buying activity.
- Shares of CCCC traded near $4.40 on Saturday, with analysts maintaining buy ratings and price targets reaching $30.
- Institutional peers like Morgan Stanley and Vanguard Capital Management LLC showed varied activity in CCCC stock.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Stephen Fawell recently purchased 62,000 shares of CCCC on June 24, 2026. This transaction is part of a broader pattern of insider buying at the company, which has seen multiple executives acquiring shares.
Insider Buying and Selling at C4 Therapeutics, Inc.
In addition to Stephen Fawell, insiders such as Laura Bessen and Donna Roy Grogan also bought 62,000 shares each on the same day. Kenneth Carl Anderson made several transactions, including buying 1,070 shares at $2.11 on June 1, 2026, and 4,259 shares at $2.70 on April 1, 2026.
Other Institutional Activity in CCCC
Morgan Stanley increased its holdings in CCCC by 90,738 shares, bringing its total to 9,072,400 shares valued at approximately $23.86 million. RA Capital Management, L.P. maintained its position with 8,000,000 shares worth about $21.04 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 3,861,852 shares valued at $10.16 million.
C4 Therapeutics, Inc. Stock Up 14.3%
Shares of CCCC traded near $4.40 on Saturday. Analysts have maintained a positive outlook on the stock, with Evercore ISI Group keeping a buy rating and a price target of $12 as of June 1, 2026. CCCC's stock has been the subject of several bullish analyst reports, with price targets reaching as high as $30.
$CCCC stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 1, 2026, Evercore ISI Group maintained its buy rating on CCCC, setting a price target of $12. Barclays has also reiterated its buy stance with varying targets, including $7 and $5 in recent months. Brookline Capital set a notably high target of $30, reflecting strong confidence in the stock's potential.
Bottom Line
Stephen Fawell's recent purchase of CCCC shares is part of a series of insider buy actions, suggesting confidence in the company. Institutional investors have shown mixed activity, with some increasing and others maintaining their stakes. Analysts remain bullish, with several maintaining buy ratings and setting ambitious price targets. This insider and institutional activity, combined with positive analyst sentiment, highlights the market's interest in CCCC.
Get C4 Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CCCC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.